Clal Biotechnology (Israel) Top Management
| CBI Stock | 45.00 0.80 1.81% |
Clal Biotechnology employs about 21 people. The company is managed by 21 executives with a total tenure of roughly 184 years, averaging almost 8.0 years of service per executive, having 1.0 employees per reported executive. Analysis of Clal Biotechnology's management performance can provide insight into the company performance.
| Avraham Fischer Chairman Chairman of the Board |
| Ofer Gonen President Vice President |
Clal |
Clal Biotechnology Management Team Effectiveness
The company has return on total asset (ROA) of (0.1194) % which means that it has lost $0.1194 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4545) %, meaning that it generated substantial loss on money invested by shareholders. Clal Biotechnology's management efficiency ratios could be used to measure how well Clal Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities.Clal Biotechnology Workforce Comparison
Clal Biotechnology Industries is number one stock in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 94.0. Clal Biotechnology totals roughly 21.0 in number of employees claiming about 22% of equities under Health Care industry.
The company has Profit Margin (PM) of (1.14) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.86) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.86. Clal Biotechnology Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Clal Biotechnology Price Series Summation is a cross summation of Clal Biotechnology price series and its benchmark/peer.
Clal Biotechnology Notable Stakeholders
A Clal Biotechnology stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Clal Biotechnology often face trade-offs trying to please all of them. Clal Biotechnology's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Clal Biotechnology's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Avraham Fischer | Chairman of the Board | Profile | |
| Ofer Gonen | Vice President | Profile | |
| Julian Adams | President Chief Scientific Officer | Profile | |
| Sigalia Heifetz | Director | Profile | |
| Shmuel Rubinstein | External Director | Profile | |
| Tomer Babai | Director | Profile | |
| Dafna Gruber | Director | Profile | |
| Aharon Schwartz | Director | Profile | |
| Gavriel Barabash | Director | Profile | |
| Isaac Kohlberg | Director | Profile | |
| Nofar Malovani | Director | Profile | |
| Yuval Yanai | External Director | Profile | |
| Ofer Goldberg | VP | Profile | |
| Orit Lidor | VP and General Counsel | Profile | |
| Iris Sadeh | Accountant | Profile | |
| Liat Nissan | Controller | Profile | |
| Arnon MD | Medical Director | Profile | |
| Pr MD | VP MediWound | Profile | |
| Assaf Segal | Acting Officer | Profile | |
| Shiran Manor | Co Sec | Profile | |
| Etty Kliger | VP MediWound | Profile |
About Clal Biotechnology Management Performance
The success or failure of an entity such as Clal Biotechnology often depends on how effective the management is. Clal Biotechnology management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Clal management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Clal management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Clal Biotechnology Industries Ltd. is a private equity and venture capital firm specializing in development stage, pre-clinical incubation, seed, start-up, early venture, emerging growth, mid venture, late venture, PIPEs, and growth capital stages of financing. It operates as a subsidiary of Clal Industries and Investments Ltd. CLAL BIOTECHNOLOGY operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange.
The data published in Clal Biotechnology's official financial statements usually reflect Clal Biotechnology's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Clal Biotechnology. For example, before you start analyzing numbers published by Clal accountants, it's critical to develop an understanding of what Clal Biotechnology's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Clal Biotechnology's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Clal Biotechnology's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Clal Biotechnology's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Clal Biotechnology Industries. Please utilize our Beneish M Score to check the likelihood of Clal Biotechnology's management manipulating its earnings.
Clal Biotechnology Workforce Analysis
Traditionally, organizations such as Clal Biotechnology use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Clal Biotechnology within its industry.Clal Biotechnology Manpower Efficiency
Return on Clal Biotechnology Manpower
| Revenue Per Employee | 3.7M | |
| Revenue Per Executive | 3.7M | |
| Net Loss Per Employee | 4.3M | |
| Net Loss Per Executive | 4.3M | |
| Working Capital Per Employee | 9.2M | |
| Working Capital Per Executive | 9.2M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Clal Biotechnology Industries. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Complementary Tools for Clal Stock analysis
When running Clal Biotechnology's price analysis, check to measure Clal Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clal Biotechnology is operating at the current time. Most of Clal Biotechnology's value examination focuses on studying past and present price action to predict the probability of Clal Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clal Biotechnology's price. Additionally, you may evaluate how the addition of Clal Biotechnology to your portfolios can decrease your overall portfolio volatility.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |